McGuff Pharmaceuticals
CompanyUnited States
McGuff Pharmaceuticals develops one asset, in phase 1 (Ascor L 500 in pharmacokinetic). Mostly small molecule acting on Oxidative stress and ROS signalling; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 1
- 1
- Trial
- 0
- Signals
Pipeline
1Essential antioxidant and enzyme cofactor involved in collagen synthesis and cellular redox defense
Phase 1, Small molecule, Oxidative stress and ROS signalling, pharmacokinetic
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials4
- Similar companies6